TheEdgeResearch
Home / Stocks / JAZZ

Jazz Pharmaceuticals plc (JAZZ)

NASDAQ Healthcare Biotechnology
$251.58 ▼ -0.51%
Market Cap
$15.80B
Sector
Healthcare
Industry
Biotechnology
Beta
0.36
52-Wk Range
105-261.3
CEO
Renee D. Gala
Country
IE
Currency
USD

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic…

Open full interactive analysis & DCF →